Guilin Sanjin Pharmaceutical Co (002275) Fair Value & Analysis

Healthcare · CN · Market cap 7.3B CNY

A strong business, screening 21% undervalued on our models.

What matters now

• Our model range runs from ¥12.16 (bear) to ¥20.27 (bull), base ¥16.22. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 78/100 (high quality) with high evidence: the data supports the verdict.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.

How to read this chart

60‑month range ¥8.65 – ¥18.46 · fair‑value band ¥12.16 – ¥20.27 · the ¥13.36 price screens below the ¥16.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Guilin Sanjin Pharmaceutical Co (002275) currently trades at ¥13.36, while our model-based Fair Value estimate is ¥16.22, implying the stock looks roughly 21.4% undervalued today. The Quality Score stands at 78/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Over the trailing twelve months, Guilin Sanjin Pharmaceutical Co generated revenue of 2.1B CNY at a net margin of 21.5%. Revenue grew 12.5% year over year. It earns a return on equity of 14.0%. The balance sheet holds a net cash position of 574M CNY. Fundamentals as of Jul 22, 2026

Our scenario range runs from ¥12.16 (bear case) to ¥20.27 (bull case); at ¥13.36, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 21%, 002275 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥16.32) versus Asset-Based (¥3.64). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally.

Full company description

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache capsule, compound panax notoginseng stomach pain tablets, Sanqi xueshangning capsules, Sanqi xueshangning powder, compound luo han guo qing fei granules, compound luo han guo lung clearing syrup, compound red root tablets, Shuanghu zhongtongning, liver and kidney tonic granules, and jade leaf detoxification granules. Its products are used in various therapeutic areas, such as urinary system disease, oral and throat, cardiovascular and cerebrovascular disease, neurological diseases, respiratory disease, digestive system disease, internal medicine, musculoskeletal system diseases, and tonic drugs. Guilin Sanjin Pharmaceutical Co., Ltd. was founded in 1985 and is headquartered in Guilin, China. Guilin Sanjin Pharmaceutical Co., Ltd. operates as a subsidiary of Guilin SanJin Group Co.,Ltd.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Guilin Sanjin Pharmaceutical Co reported revenue of ¥2.0B in FY2025 versus ¥1.7B in FY2021, a compound +4.1%/yr. Reported net income was ¥433M in FY2025, compounding +6.0%/yr from FY2021.

Watch 002275: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.